– AMS-17 is a potent NLRP3 inhibitor that effectively suppresses microglia activation both in vitro and in vivo. Moreover, AMS-17 exhibits inhibitory effects on various cytokines, such as caspase-1, TNF-α, IL-1β, and inducible nitric oxide synthase (iNOS), in N9 cells, making it a promising tool for investigating inflammation-associated neurological disorders [1].